[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612519":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":181,"collaborators":183,"id":187,"slug":188,"hasResults":189,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":189,"sex":195,"minAge":196,"maxAge":11,"enrollmentInfo":197,"targetDuration":11,"studyType":200,"phases":201,"briefSummary":203,"conditions":204,"keywords":11,"overallStatus":206,"whyStopped":11,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tocilizumab","EXPERIMENTAL",null,[13],"Drug: Tocilizumab",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Tocilizumab, 8 mg\u002Fkg\u002Fmonth, IV infusion for 3 months\n\nTocilizumab, an anti-IL-6R monoclonal antibody, was approved in January 2009 for the treatment of rheumatoid arthritis. Its indications have since been extended, particularly for the treatment of giant cell arteritis, juvenile chronic arthritis, and severe cytokine release syndrome induced by chimeric antigen receptor T-cell (CAR-T) therapy.",[9],{"type":6,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Saline placebo, IV infusion \u002F month for 3 months",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Augustin Latourte, Associate Professor","CONTACT","+33 1 49 95 62 90","augustin.latourte@aphp.fr",[34,52,62,76,90,104,115,126,136,147,153,167],{"facility":35,"status":11,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Groupe Hospitalier de l'Institut Catholique de Lille","Lomme","Lille","59462","France","FR",{"type":42,"coordinates":43},"Point",[44,45],2.98715,50.64358,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":50,"phoneExt":11,"email":51},"PASCART Tristan, Dr","0320225059","pascart.tristan@ghicl.net",{"facility":53,"status":11,"city":54,"state":55,"zip":56,"country":39,"countryCode":40,"cosmosGeoPoint":57,"geoPoint":61,"contacts":11},"Lariboisière hospital","Paris","Paris Paris","75010",{"type":42,"coordinates":58},[59,60],2.3488,48.85341,{"lat":60,"lon":59},{"facility":63,"status":11,"city":64,"state":54,"zip":65,"country":39,"countryCode":40,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Centre Hospitalier Sud-Francilien","Corbeil-Essonnes","91100",{"type":42,"coordinates":67},[68,69],2.48757,48.60603,{"lat":69,"lon":68},[72],{"name":73,"role":30,"phone":74,"phoneExt":11,"email":75},"HILLIQUIN Pascal, Dr","0161693128","pascal.hilliquin@chsf.fr",{"facility":77,"status":11,"city":78,"state":11,"zip":79,"country":39,"countryCode":40,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CHU de Dijon","Dijon","21000",{"type":42,"coordinates":81},[82,83],5.01391,47.31344,{"lat":83,"lon":82},[86],{"name":87,"role":30,"phone":88,"phoneExt":11,"email":89},"RAMON André, Dr","0380293745","andre.ramon@chu-dijon.fr",{"facility":91,"status":11,"city":92,"state":11,"zip":93,"country":39,"countryCode":40,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"CHU de Nantes","Nantes","44000",{"type":42,"coordinates":95},[96,97],-1.55336,47.21725,{"lat":97,"lon":96},[100],{"name":101,"role":30,"phone":102,"phoneExt":11,"email":103},"LE GOFF Benoit, Dr","0240083333","benoit.legoff@chu-nantes.fr",{"facility":105,"status":11,"city":54,"state":11,"zip":106,"country":39,"countryCode":40,"cosmosGeoPoint":107,"geoPoint":109,"contacts":110},"Hôpital Bichat Claude-Bernard","75018",{"type":42,"coordinates":108},[59,60],{"lat":60,"lon":59},[111],{"name":112,"role":30,"phone":113,"phoneExt":11,"email":114},"OTTAVIANI Sébastien","0140258739","sebastien.ottaviani@aphp.fr",{"facility":116,"status":11,"city":54,"state":11,"zip":117,"country":39,"countryCode":40,"cosmosGeoPoint":118,"geoPoint":120,"contacts":121},"Hôpital de la Croix Saint-Simon","75020",{"type":42,"coordinates":119},[59,60],{"lat":60,"lon":59},[122],{"name":123,"role":30,"phone":124,"phoneExt":11,"email":125},"CHAZERAIN Pascal, Dr","0144641782","PChazerain@hopital-dcss.org",{"facility":127,"status":11,"city":54,"state":11,"zip":117,"country":39,"countryCode":40,"cosmosGeoPoint":128,"geoPoint":130,"contacts":131},"Hôpital Tenon",{"type":42,"coordinates":129},[59,60],{"lat":60,"lon":59},[132],{"name":133,"role":30,"phone":134,"phoneExt":11,"email":135},"LETAVERNIER Emmanuel, Pr","0156016773","emmanuel.letavernier@aphp.fr",{"facility":137,"status":11,"city":54,"state":11,"zip":138,"country":39,"countryCode":40,"cosmosGeoPoint":139,"geoPoint":141,"contacts":142},"Groupe Hospitalier Intercommunal Le Raincy-Montfermeil","93370",{"type":42,"coordinates":140},[59,60],{"lat":60,"lon":59},[143],{"name":144,"role":30,"phone":145,"phoneExt":11,"email":146},"DELLAL Azzedine, Dr","0141708766","azeddine.dellal@ght-gpne.fr",{"facility":148,"status":11,"city":54,"state":11,"zip":149,"country":39,"countryCode":40,"cosmosGeoPoint":150,"geoPoint":152,"contacts":11},"Hôpital Le Kremlin Bicêtre","94270",{"type":42,"coordinates":151},[59,60],{"lat":60,"lon":59},{"facility":154,"status":11,"city":155,"state":11,"zip":156,"country":39,"countryCode":40,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"CHU de Rennes","Rennes","35200",{"type":42,"coordinates":158},[159,160],-1.67431,48.11109,{"lat":160,"lon":159},[163],{"name":164,"role":30,"phone":165,"phoneExt":11,"email":166},"CHOTARD Emilie, Dr","0299267140","Emilie.CHOTARD@chu-rennes.fr",{"facility":168,"status":11,"city":169,"state":11,"zip":170,"country":39,"countryCode":40,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"CHU de Saint-Étienne","Saint-Etienne","42100",{"type":42,"coordinates":172},[173,174],4.39,45.43389,{"lat":174,"lon":173},[177],{"name":178,"role":30,"phone":179,"phoneExt":11,"email":180},"MAROTTE Hubert, Pr","0477127643","hubert.marotte@chu-st-etienne.fr",{"type":182,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[184],{"name":185,"class":186},"Fresenius AG","INDUSTRY","100612519","phase-2-tocilizumab-in-chronic-inflammatory-cppd-disease-100612519",false,"NCT07254637","Tocilizumab in Chronic Inflammatory CPPD Disease","Randomized, Double-blind, Multicentre Trial of Tocilizumab Versus Placebo in Chronic Polyarticular Inflammatory of Calcium Pyrophosphate Deposition Disease Refractory to Standard Treatments","TociCCAre","Inclusion Criteria:\n\n* Adults \\> 18 years\n* Diagnosis of CPPD according to ACR\u002FEULAR 2023 classification criteria\n* Persistent inflammatory pain (\\> 3 months) or ≥ 2 arthritics\u002Fmonth\n* Number of painful joints (NAD) \\> 3\n* Overall pain VAS (0\\_100) \\> 40 mm\n* Failure, intolerance or impossibility of repeated use of usual treatments: colchicine, NSAIDs, corticosteroids and anakinra\n* Use of an effective method of contraception in women of childbearing age until 3 months after the end of the study.\n* Informed consent\n\nExclusion Criteria:\n\n* Presence of anti-CPP antibodies \\> 50 IU\u002Fml\n* Recurrent or chronic infections\n* History of severe infection (= requiring hospitalization)\n* Active infection\n* Vaccination with live or attenuated vaccine within 4 weeks prior to inclusion\n* History of intestinal ulceration or diverticulitis Untreated latent tuberculosis\n* History of viral hepatitis B ou C\n* Symptoms suggestive of demyelinating disease of the central nervous system\n* History of cancer, active cancer, or suspected cancer\n* Neutropenia \\\u003C 2000 elements\u002Fmm3, thrombocytopenia \\\u003C 100 000\u002Fmm3\n* Elevated transaminases \\> 3 x ULN\n* Known hypersensitivity to the active substance or one of the excipients;\n* Known severe immune deficiency\n* Patients not meeting classification criteria\n* Concomitant treatment with biological or targeted therapies, or immunosuppressive therapy (including methotrexate, leflunomide, azathioprine), systemic corticosteroids, anakinra, IL-6 inhibitors in subcutaneous injection, anti-TNF agents, and JAK. If these treatments are used before inclusion, a washout period corresponding to at least five times their respective mean terminal half-life must be respected.\n* inhibitors.\n* Previous treatment with tocilizumab\n* Concomitant treatment with methylprednisolone, dexamethasone, atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, cyclosporine or benzodiazepines\n* Dyslipidemia, hypertension or poorly controlled cardiovascular disease\n* Scheduled surgery\n* Difficulty to understand French, illiteracy\n* Pregnant women, women in labor or nursing mothers\n* Persons deprived of their liberty, adults under legal protection or unable to express their consent\n* Persons not affiliated to a social security scheme or beneficiaries of such a scheme\n* Participation in another interventional study","ALL","18 Years",{"count":198,"type":199},80,"ESTIMATED","INTERVENTIONAL",[202],"PHASE2","The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.\n\nThe main questions this trial aims to answer are:\n\n* Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease?\n* Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease?\n\nParticipants will receive a monthly infusion of tocilizumab or placebo for three months.",[205],"Calcium Pyrophosphate Deposition Disease","NOT_YET_RECRUITING","2026-01-13",{"date":209,"type":210},"2026-01-14","ACTUAL",{"date":212,"type":199},"2026-04",{"date":214,"type":199},"2029-11",{"name":5,"class":6},12]